Loading...

Janet Cowan

Title(s)Manager, UCATS Stats Group, Urology
SchoolSchool of Medicine
Address550 16th. Street
San Francisco CA 94158
Phone415-353-7424
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    I am a statistical programmer and manager of the UCATS Stats Group in the UCSF Department of Urology Clinical and Translational Sciences. I work closely with Peter R. Carroll, other faculty, and trainees specializing in urologic oncology. My work focuses on health outcomes in men with prostate cancer, particularly patients managed with active surveillance or radical prostatectomy.

    Please identify me as Janet E. Cowan, MA for authorship.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2021 Jan 19. Chu CE, Cowan JE, Lonergan PE, Washington SL, Fasulo V, de la Calle CM, Shinohara K, Westphalen AC, Carroll PR. PMID: 33483265.
      View in: PubMed   Mentions:    Fields:    
    2. The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance-Does Cancer Vanish or Simply Hide? J Urol. 2021 Jan; 205(1):109-114. PMID: 33198555.
      View in: PubMed   Mentions:    Fields:    
    3. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020 12; 204(6):1222-1228. Maggi M, Cowan JE, Fasulo V, Washington SL, Lonergan PE, Sciarra A, Nguyen HG, Carroll PR. PMID: 33157570.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Multiple Tissue Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes. Eur Urol. 2021 Jan; 79(1):141-149. Cooperberg MR, Cowan JE, Lindquist KJ, Kobayashi Y, Simko JP, Bengtsson H, Singh K, Ngo V, Avila A, Newcomb LF, Tretriakova M, Lin DW, Stone S, Carroll PR, Paris PL. PMID: 33148472.
      View in: PubMed   Mentions:    Fields:    
    5. Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. Prostate. 2021 Feb; 81(2):102-108. Washington SL, Cowan JE, Herlemann A, Zuniga KB, Masic S, Nguyen HG, Carroll PR. PMID: 33075151.
      View in: PubMed   Mentions:    Fields:    
    6. Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. Eur Urol Oncol. 2020 Oct 14. Fasulo V, Cowan JE, Maggi M, Washington SL, Nguyen HG, Shinohara K, Lazzeri M, Casale P, Carroll PR. PMID: 33069628.
      View in: PubMed   Mentions:    Fields:    
    7. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability. JAMA Oncol. 2020 Oct 01; 6(10):e203187. Cooperberg MR, Zheng Y, Faino AV, Newcomb LF, Zhu K, Cowan JE, Brooks JD, Dash A, Gleave ME, Martin F, Morgan TM, Nelson PS, Thompson IM, Wagner AA, Carroll PR, Lin DW. PMID: 32852532.
      View in: PubMed   Mentions:    Fields:    
    8. Reply by Authors. J Urol. 2020 12; 204(6):1221. Lonergan PE, Washington SL, Cowan JE, Zhao S, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. PMID: 32969756.
      View in: PubMed   Mentions:    Fields:    
    9. Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category. Prostate. 2020 12; 80(16):1421-1428. Greenland NY, Cowan JE, Chan E, Carroll PR, Stohr BA, Simko JP. PMID: 32946625.
      View in: PubMed   Mentions:    Fields:    
    10. Clinical Utility of 4Kscore®, ExosomeDx™ and Magnetic Resonance Imaging for the Early Detection of High Grade Prostate Cancer. J Urol. 2021 Feb; 205(2):452-460. de la Calle CM, Fasulo V, Cowan JE, Lonergan PE, Maggi M, Gadzinski AJ, Yeung RA, Saita A, Cooperberg MR, Shinohara K, Carroll PR, Nguyen HG. PMID: 32897802.
      View in: PubMed   Mentions:    Fields:    
    11. How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound? Eur Urol Focus. 2020 Aug 28. Herlemann A, Overland MR, Washington SL, Cowan JE, Westphalen AC, Carroll PR, Nguyen HG, Shinohara K, Cooperberg MR. PMID: 32868222.
      View in: PubMed   Mentions:    Fields:    
    12. Examining initial treatment and survival among men with metastatic prostate cancer: An analysis from the CaPSURE registry. Urol Oncol. 2020 Oct; 38(10):793.e1-793.e11. PMID: 32782182.
      View in: PubMed   Mentions:    Fields:    
    13. Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. Eur Urol. 2020 10; 78(4):515-517. Chu CE, Lonergan PE, Washington SL, Cowan JE, Shinohara K, Westphalen AC, Carroll PR, Cooperberg MR. PMID: 32631744.
      View in: PubMed   Mentions:    Fields:    
    14. Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2020 12; 204(6):1216-1221. Lonergan PE, Washington SL, Cowan JE, Zhao S, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. PMID: 32519915.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. The Relative Impact of Urinary and Sexual Function vs Bother on Health Utility for Men With Prostate Cancer. JNCI Cancer Spectr. 2020 Oct; 4(5):pkaa044. Jeong CW, Herlemann A, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR. PMID: 33134826.
      View in: PubMed   Mentions:
    16. Expansile cribriform Gleason pattern 4 has histopathologic and molecular features of aggressiveness and greater risk of biochemical failure compared to glomerulation Gleason pattern 4. Prostate. 2020 05; 80(8):653-659. Greenland NY, Cowan JE, Zhang L, Carroll PR, Chan E, Stohr BA, Simko JP. PMID: 32220141.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    17. Development and pilot evaluation of a personalized decision support intervention for low risk prostate cancer patients. Cancer Med. 2020 01; 9(1):125-132. Belkora J, Chan JM, Cooperberg MR, Neuhaus J, Stupar L, Weinberg T, Broering JM, Tenggara I, Cowan JE, Rosenfeld S, Kenfield SA, Van Blarigan EL, Simko JP, Witte J, Carroll PR. PMID: 31714037.
      View in: PubMed   Mentions: 1     Fields:    
    18. Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts. Cancer. 2020 02 01; 126(3):583-592. Lange JM, Laviana AA, Penson DF, Lin DW, Bill-Axelson A, Carlsson SV, Newcomb LF, Trock BJ, Carter HB, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Etzioni RB. PMID: 31639200.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Trends in Complementary and Alternative Medicine Use among Patients with Prostate Cancer. J Urol. 2019 10; 202(4):689-695. Zuniga KB, Zhao S, Kenfield SA, Cedars B, Cowan JE, Van Blarigan EL, Broering JM, Carroll PR, Chan JM. PMID: 31091175.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    20. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. J Urol. 2019 10; 202(4):696-701. Cedars BE, Washington SL, Cowan JE, Leapman M, Tenggara I, Chan JM, Cooperberg MR, Carroll PR. PMID: 30958742.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. A 17-Gene Genomic Prostate Score as a Predictor of Adverse Pathology in Men on Active Surveillance. J Urol. 2019 10; 202(4):702-709. Kornberg Z, Cooperberg MR, Cowan JE, Chan JM, Shinohara K, Simko JP, Tenggara I, Carroll PR. PMID: 31026214.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    22. Obesity at Diagnosis and Prostate Cancer Prognosis and Recurrence Risk Following Primary Treatment by Radical Prostatectomy. Cancer Epidemiol Biomarkers Prev. 2019 11; 28(11):1917-1925. Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM. PMID: 31462398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance. J Urol. 2019 09; 202(3):506-510. Balakrishnan AS, Cowan JE, Cooperberg MR, Shinohara K, Nguyen HG, Carroll PR. PMID: 30958738.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    24. Robust Health Utility Assessment Among Long-term Survivors of Prostate Cancer: Results from the Cancer of the Prostate Strategic Urologic Research Endeavor Registry. Eur Urol. 2019 12; 76(6):743-751. Jeong CW, Cowan JE, Broering JM, Ten Ham RMT, Wilson LS, Carroll PR, Cooperberg MR. PMID: 31345635.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    25. Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research. JCO Clin Cancer Inform. 2019 07; 3:1-8. Odisho AY, Bridge M, Webb M, Ameli N, Eapen RS, Stauf F, Cowan JE, Washington SL, Herlemann A, Carroll PR, Cooperberg MR. PMID: 31314550.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    26. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer. J Urol. 2019 07; 202(1):90-95. Greenland NY, Zhang L, Cowan JE, Carroll PR, Stohr BA, Simko JP. PMID: 30810466.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    27. Trends and Predictors of Adjuvant Therapy for Adverse Features Following Radical Prostatectomy: An Analysis From Cancer of the Prostate Strategic Urologic Research Endeavor. Urology. 2019 Sep; 131:157-165. Balakrishnan AS, Zhao S, Cowan JE, Broering JM, Cooperberg MR, Carroll PR. PMID: 31150694.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance. J Urol. 2019 02; 201(2):300-307. Kornberg Z, Cowan JE, Westphalen AC, Cooperberg MR, Chan JM, Zhao S, Shinohara K, Carroll PR. PMID: 30179620.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    29. Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. Eur Urol Oncol. 2019 11; 2(6):685-690. Xu MJ, Kornberg Z, Gadzinski AJ, Diao D, Cowan JE, Wu SY, Boreta L, Spratt DE, Behr SC, Nguyen HG, Cooperberg MR, Davicioni E, Roach M, Hope TA, Carroll PR, Feng FY. PMID: 31411984.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    30. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. Eur Urol Oncol. 2019 05; 2(3):333-336. van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, Hyndman E, Moore CM, Gnanapragasam V, Van Hemelrijck M, Dasgupta P, Bangma C, Roobol M, Villers A, Rannikko A, Valdagni R, Perry A, Hugosson J, Rubio-Briones J, Bjartell A, Hefermehl L, Shiong LL, Frydenberg M, Kakehi Y, Chung BH, van der Kwast T, Obbink H, van der Linden W, Hulsen T, de Jonge C, Kattan M, Xinge J, Muir K, Lophatananon A, Fahey M, Steyerberg E, Nieboer D, Zhang L, Guo W, Benfante N, Cowan J, Patil D, Tolosa E, Kim TK, Mamedov A, LaPointe V, Crump T, Kimberly-Duffell J, Santaolalla A, Nieboer D, Olivier JT, Rancati T, Ahlgren H, Mascarós J, Löfgren A, Lehmann K, Lin CH, Hirama H, Lee KS, Jenster G, Auvinen A, Bjartell A, Haider M, van Bochove K, Carter B, Gledhill S, Buzza M, Bangma C, Roobol M, Bruinsma S, Helleman J. PMID: 31200849.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    31. ESTIMATING AND COMPARING CANCER PROGRESSION RISKS UNDER VARYING SURVEILLANCE PROTOCOLS. Ann Appl Stat. 2018 Sep; 12(3):1773-1795. Lange JM, Gulati R, Leonardson AS, Lin DW, Newcomb LF, Trock BJ, Carter HB, Cooperberg MR, Cowan JE, Klotz LH, Etzioni R. PMID: 30627300.
      View in: PubMed   Mentions:
    32. Comparing Prognostic Utility of a Single-marker Immunohistochemistry Approach with Commercial Gene Expression Profiling Following Radical Prostatectomy. Eur Urol. 2018 11; 74(5):668-675. Leapman MS, Nguyen HG, Cowan JE, Xue L, Stohr B, Simko J, Cooperberg MR, Carroll PR. PMID: 30181067.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    33. Practice patterns of primary EBRT with and without ADT in prostate cancer treatment. Prostate Cancer Prostatic Dis. 2019 03; 22(1):117-124. Schmidt B, Eapen RS, Cowan JE, Broering JM, Greene KL, Carroll PR, Cooperberg MR. PMID: 30171230.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    34. The Diverse Genomic Landscape of Clinically Low-risk Prostate Cancer. Eur Urol. 2018 10; 74(4):444-452. Cooperberg MR, Erho N, Chan JM, Feng FY, Fishbane N, Zhao SG, Simko JP, Cowan JE, Lehrer J, Alshalalfa M, Kolisnik T, Chelliserry J, Margrave J, Aranes M, Plessis MD, Buerki C, Tenggara I, Davicioni E, Carroll PR. PMID: 29853306.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    35. Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. Eur Urol Oncol. 2018 10; 1(5):386-394. Masic S, Cowan JE, Washington SL, Nguyen HG, Shinohara K, Cooperberg MR, Carroll PR. PMID: 31158077.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    36. Development of a stress response therapy targeting aggressive prostate cancer. Sci Transl Med. 2018 05 02; 10(439). Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. PMID: 29720449.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    37. Comparative Analysis of Biopsy Upgrading in Four Prostate Cancer Active Surveillance Cohorts. Ann Intern Med. 2018 01 02; 168(1):1-9. Inoue LYT, Lin DW, Newcomb LF, Leonardson AS, Ankerst D, Gulati R, Carter HB, Trock BJ, Carroll PR, Cooperberg MR, Cowan JE, Klotz LH, Mamedov A, Penson DF, Etzioni R. PMID: 29181514.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    38. Milk and other dairy foods in relation to prostate cancer recurrence: Data from the cancer of the prostate strategic urologic research endeavor (CaPSURE™). Prostate. 2018 Jan; 78(1):32-39. Tat D, Kenfield SA, Cowan JE, Broering JM, Carroll PR, Van Blarigan EL, Chan JM. PMID: 29105845.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimals
    39. Community-based Outcomes of Open versus Robot-assisted Radical Prostatectomy. Eur Urol. 2018 02; 73(2):215-223. Herlemann A, Cowan JE, Carroll PR, Cooperberg MR. PMID: 28499617.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    40. Active Surveillance in Younger Men With Prostate Cancer. J Clin Oncol. 2017 Jun 10; 35(17):1898-1904. PMID: 28346806.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    41. Interpreting Patient Reported Urinary and Sexual Function Outcomes across Multiple Validated Instruments. J Urol. 2017 09; 198(3):671-677. PMID: 28342935.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    42. Application of a Prognostic Gleason Grade Grouping System to Assess Distant Prostate Cancer Outcomes. Eur Urol. 2017 05; 71(5):750-759. PMID: 27940155.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    43. A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control after Robotic Assisted Radical Prostatectomy. J Urol. 2017 02; 197(2):369-375. PMID: 27693447.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    44. Magnetic Resonance Imaging-Ultrasound Fusion Biopsy During Prostate Cancer Active Surveillance. Eur Urol. 2017 08; 72(2):275-281. PMID: 27595378.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    45. Serial Anatomical Prostate Ultrasound during Prostate Cancer Active Surveillance. J Urol. 2016 Sep; 196(3):727-33. PMID: 27117443.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    46. The Molecular Taxonomy of Primary Prostate Cancer. Cell. 2015 Nov 05; 163(4):1011-25. PMID: 26544944.
      View in: PubMed   Mentions: 626     Fields:    Translation:HumansCells
    47. Immediate versus delayed radical prostatectomy: updated outcomes following active surveillance of prostate cancer. Eur Urol. 2015 Sep; 68(3):458-63. PMID: 26138041.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Patterns of Local Failure following Radiation Therapy for Prostate Cancer. J Urol. 2015 Oct; 194(4):977-82. PMID: 25983194.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    49. Impact of age on quality-of-life outcomes after treatment for localized prostate cancer. Eur Urol. 2015 Sep; 68(3):480-6. PMID: 25656807.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    50. Current Use of Imaging after Primary Treatment of Prostate Cancer. J Urol. 2015 Jul; 194(1):98-104. PMID: 25640648.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    51. Untreated Gleason Grade Progression on Serial Biopsies during Prostate Cancer Active Surveillance: Clinical Course and Pathological Outcomes. J Urol. 2015 Jul; 194(1):85-90. PMID: 25623742.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    52. Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. J Urol. 2015 Mar; 193(3):807-11. PMID: 25261803.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    53. Long-term health-related quality of life after primary treatment for localized prostate cancer: results from the CaPSURE registry. Eur Urol. 2015 Oct; 68(4):600-8. PMID: 25242555.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    54. miR-19, miR-345, miR-519c-5p serum levels predict adverse pathology in prostate cancer patients eligible for active surveillance. PLoS One. 2014; 9(6):e98597. PMID: 24893170.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    55. A 17-gene assay to predict prostate cancer aggressiveness in the context of Gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. Eur Urol. 2014 Sep; 66(3):550-60. PMID: 24836057.
      View in: PubMed   Mentions: 158     Fields:    Translation:HumansCells
    56. Racial variation in prostate cancer upgrading and upstaging among men with low-risk clinical characteristics. Eur Urol. 2015 Mar; 67(3):451-7. PMID: 24746973.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    57. A risk-adjusted definition of biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2014 Jun; 17(2):174-9. PMID: 24614692.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    58. Age and baseline quality of life at radical prostatectomy--who has the most to lose? J Urol. 2014 Aug; 192(2):396-401. PMID: 24582539.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    59. Limited ability of existing nomograms to predict outcomes in men undergoing active surveillance for prostate cancer. BJU Int. 2014 Dec; 114(6b):E18-E24. PMID: 24712895.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    60. Serial prostate biopsy and risk of lower urinary tract symptoms: results from a large, single-institution active surveillance cohort. Urology. 2014 Jan; 83(1):33-8. PMID: 24246319.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    61. Impact of androgen deprivation therapy on mental and emotional well-being in men with prostate cancer: analysis from the CaPSURE™ registry. J Urol. 2014 Apr; 191(4):964-70. PMID: 24184370.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    62. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies. Eur Urol. 2014 Aug; 66(2):337-42. PMID: 24035632.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    63. Autologous retro-pubic urethral sling: a novel, quick, intra-operative technique to improve continence after robotic-assisted radical prostatectomy. J Robot Surg. 2014 Jun; 8(2):99-104. PMID: 27637518.
      View in: PubMed   Mentions:    Fields:    
    64. A longitudinal study of anxiety, depression and distress as predictors of sexual and urinary quality of life in men with prostate cancer. BJU Int. 2013 Jul; 112(2):E67-75. PMID: 23795800.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    65. Patient demographics, quality of life, and disease features of men with newly diagnosed prostate cancer: trends in the PSA era. Urology. 2013 Jul; 82(1):60-5. PMID: 23706257.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    66. Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology. 2013 Jul; 82(1):154-9. PMID: 23522995.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    67. How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? BJU Int. 2013 Aug; 112(4):E314-20. PMID: 23451984.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    68. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J Clin Oncol. 2013 Apr 10; 31(11):1428-34. PMID: 23460710.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    69. Active surveillance: does serial prostate biopsy increase histological inflammation? Prostate Cancer Prostatic Dis. 2013 Jun; 16(2):165-9. PMID: 23318528.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. A model for the design and construction of a resource for the validation of prognostic prostate cancer biomarkers: the Canary Prostate Cancer Tissue Microarray. Adv Anat Pathol. 2013 Jan; 20(1):39-44. PMID: 23232570.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    71. Do adenocarcinomas of the prostate with Gleason score (GS) =6 have the potential to metastasize to lymph nodes? Am J Surg Pathol. 2012 Sep; 36(9):1346-52. PMID: 22531173.
      View in: PubMed   Mentions: 68     Fields:    Translation:Humans
    72. Factors associated with satisfaction with prostate cancer care: results from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). BJU Int. 2013 Feb; 111(2):213-20. PMID: 22928860.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    73. Aspirin use and the risk of prostate cancer mortality in men treated with prostatectomy or radiotherapy. J Clin Oncol. 2012 Oct 01; 30(28):3540-4. PMID: 22927523.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    74. The impact of serial prostate biopsies on sexual function in men on active surveillance for prostate cancer. J Urol. 2012 Oct; 188(4):1252-8. PMID: 22902015.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    75. Local staging of prostate cancer: comparative accuracy of T2-weighted endorectal MR imaging and transrectal ultrasound. Clin Imaging. 2012 Sep-Oct; 36(5):547-52. PMID: 22920360.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    76. The quantitative Gleason score improves prostate cancer risk assessment. Cancer. 2012 Dec 15; 118(24):6046-54. PMID: 22674220.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    77. PSA screening: determinants of primary-care physician practice patterns. Prostate Cancer Prostatic Dis. 2012 Jun; 15(2):189-94. PMID: 22343837.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    78. Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. BJU Int. 2012 Jul; 110(1):50-5. PMID: 22077660.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    79. Changes in cancer volume in serial biopsies of men on active surveillance for early stage prostate cancer. J Urol. 2011 Nov; 186(5):1825-9. PMID: 21944082.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    80. Changes in prostate cancer grade on serial biopsy in men undergoing active surveillance. J Clin Oncol. 2011 Jul 10; 29(20):2795-800. PMID: 21632511.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    81. Factors associated with downgrading in patients with high grade prostate cancer. Urol Oncol. 2013 May; 31(4):442-7. Whitson JM, Porten SP, Cowan JE, Simko JP, Cooperberg MR, Carroll PR. PMID: 21478037.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    82. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. PMID: 20804478.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    83. The relationship between prostate specific antigen change and biopsy progression in patients on active surveillance for prostate cancer. J Urol. 2011 May; 185(5):1656-60. PMID: 21419438.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansPHPublic Health
    84. Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. BJU Int. 2010 Dec; 106(11):1734-8. Breyer BN, Davis CB, Cowan JE, Kane CJ, Carroll PR. PMID: 20438567.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    85. Outcomes of active surveillance for men with intermediate-risk prostate cancer. J Clin Oncol. 2011 Jan 10; 29(2):228-34. PMID: 21115873.
      View in: PubMed   Mentions: 76     Fields:    Translation:Humans
    86. Association of statin and nonsteroidal anti-inflammatory drug use with prostate cancer outcomes: results from CaPSURE. BJU Int. 2010 Sep; 106(5):627-32. Katz MS, Carroll PR, Cowan JE, Chan JM, D'Amico AV. PMID: 20151961.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    87. Prostate specific antigen screening for prostate cancer: knowledge of, attitudes towards, and utilization among primary care physicians. Urol Oncol. 2012 Mar-Apr; 30(2):155-60. Tasian GE, Cooperberg MR, Cowan JE, Keyashian K, Greene KL, Daniels NA, Carroll PR, Chan JM. PMID: 20800514.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansPHPublic Health
    88. Prostate cancer managed with active surveillance: role of anatomic MR imaging and MR spectroscopic imaging. Radiology. 2010 Jul; 256(1):176-83. Fradet V, Kurhanewicz J, Cowan JE, Karl A, Coakley FV, Shinohara K, Carroll PR. PMID: 20505068.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansPHPublic Health
    89. Changes in specific domains of sexual function and sexual bother after radical prostatectomy. BJU Int. 2010 Oct; 106(7):1022-9. Le JD, Cooperberg MR, Sadetsky N, Hittelman AB, Meng MV, Cowan JE, Latini DM, Carroll PR. PMID: 20184571.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    90. Eligibility for active surveillance and pathological outcomes for men undergoing radical prostatectomy in a large, community based cohort. J Urol. 2010 Jan; 183(1):138-43. Smaldone MC, Cowan JE, Carroll PR, Davies BJ. PMID: 19913808.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansPHPublic Health
    91. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE. BJU Int. 2010 Apr; 105(7):951-5. Aaronson D, Cowan J, Carroll P, Konety B. PMID: 19889066.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    92. The adjunctive use of power Doppler imaging in the preoperative assessment of prostate cancer. BJU Int. 2010 May; 105(9):1237-41. Eisenberg ML, Cowan JE, Carroll PR, Shinohara K. PMID: 19888980.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    93. Adequacy of lymphadenectomy among men undergoing robot-assisted laparoscopic radical prostatectomy. BJU Int. 2010 Jan; 105(1):88-92. Cooperberg MR, Kane CJ, Cowan JE, Carroll PR. PMID: 19549119.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    94. Dispatcher assessments for agonal breathing improve detection of cardiac arrest. Resuscitation. 2009 Jul; 80(7):769-72. Roppolo LP, Westfall A, Pepe PE, Nobel LL, Cowan J, Kay JJ, Idris AH. PMID: 19477058.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    95. The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer. Urol Oncol. 2011 Mar-Apr; 29(2):171-6. Eisenberg ML, Cowan JE, Davies BJ, Carroll PR, Shinohara K. PMID: 19362864.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    96. Prognostic implications of an undetectable ultrasensitive prostate-specific antigen level after radical prostatectomy. Eur Urol. 2010 Apr; 57(4):622-9. Eisenberg ML, Davies BJ, Cooperberg MR, Cowan JE, Carroll PR. PMID: 19375843.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    97. Sociodemographic predictors of prostate cancer risk category at diagnosis: unique patterns of significant and insignificant disease. J Urol. 2009 Apr; 181(4):1622-7; discussion 1627. Dall'era MA, Hosang N, Konety B, Cowan JE, Carroll PR. PMID: 19230923.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    98. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009 Apr; 181(4):1628-33; discussion 1633-4. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. PMID: 19233388.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansPHPublic Health
    99. Pretreatment predictors of death from other causes in men with prostate cancer. J Urol. 2008 Dec; 180(6):2447-51; discussion 2451-2. Simone NL, Singh AK, Cowan JE, Soule BP, Carroll PR, Litwin MS. PMID: 18930498.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    100. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol. 2008 Oct; 180(4):1330-4; discussion 1334-5. Barocas DA, Cowan JE, Smith JA, Carroll PR. PMID: 18707731.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    101. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. PMID: 18433013.
      View in: PubMed   Mentions: 106     Fields:    Translation:HumansCTClinical Trials
    102. High-risk prostate cancer in the United States, 1990-2007. World J Urol. 2008 Jun; 26(3):211-8. Cooperberg MR, Cowan J, Broering JM, Carroll PR. PMID: 18369637.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    103. Fear of recurrence, symptom burden, and health-related quality of life in men with prostate cancer. Urology. 2008 Dec; 72(6):1269-73. Bellizzi KM, Latini DM, Cowan JE, DuChane J, Carroll PR. PMID: 18342930.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    104. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008 May; 179(5):1797-803; discussion 1803. Konety BR, Cowan JE, Carroll PR. PMID: 18343440.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    105. Fear of recurrence, treatment satisfaction, and quality of life after radical prostatectomy for prostate cancer. Support Care Cancer. 2008 Feb; 16(2):161-9. Hart SL, Latini DM, Cowan JE, Carroll PR. PMID: 17638026.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    106. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance. J Urol. 2007 Sep; 178(3 Pt 1):826-31; discussion 831-2. Latini DM, Hart SL, Knight SJ, Cowan JE, Ross PL, Duchane J, Carroll PR. PMID: 17632144.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    107. Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE. Cancer. 2007 Jul 01; 110(1):81-6. Ryan CJ, Elkin EP, Cowan J, Carroll PR. PMID: 17516446.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    108. Quality of life in young men after radical prostatectomy. Prostate Cancer Prostatic Dis. 2008; 11(1):67-73. Wright JL, Lin DW, Cowan JE, Carroll PR, Litwin MS. PMID: 17519925.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    109. Prostate brachytherapy: a descriptive analysis from CaPSURE. Brachytherapy. 2007 Apr-Jun; 6(2):123-8. Lee WR, Sharkey J, Cowan JE, DuChane J, Carroll PR. PMID: 17434105.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    110. Bladder cancer incidence and risk factors in men with prostate cancer: results from Cancer of the Prostate Strategic Urologic Research Endeavor. J Urol. 2007 Mar; 177(3):883-7; discussion 887-8. Boorjian S, Cowan JE, Konety BR, DuChane J, Tewari A, Carroll PR, Kane CJ. PMID: 17296367.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    111. Health-related quality of life for men with prostate cancer and diabetes: a longitudinal analysis from CaPSURE. Urology. 2006 Dec; 68(6):1242-7. Latini DM, Chan JM, Cowan JE, Arredondo SA, Kane CJ, Penson DF, DuChane J, Carroll PR. PMID: 17141841.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    112. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer. 2006 Apr 15; 106(8):1708-14. Kawakami J, Cowan JE, Elkin EP, Latini DM, DuChane J, Carroll PR. PMID: 16544313.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    113. Who is the average patient presenting with prostate cancer? Urology. 2005 Nov; 66(5 Suppl):76-82. Greene KL, Cowan JE, Cooperberg MR, Meng MV, DuChane J, Carroll PR. PMID: 16194711.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    114. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE (United States). Cancer Causes Control. 2005 Sep; 16(7):789-97. Chan JM, Latini DM, Cowan J, Duchane J, Carroll PR. PMID: 16132789.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    Janet's Networks
    Concepts (255)
    Derived automatically from this person's publications.
    _
    Co-Authors (55)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _